Investigating new echocardiographic markers in heart failure patients
Clinical Value of Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure
This study is testing new heart ultrasound measurements in hospitalized heart failure patients to see if they can help doctors understand different types of heart failure and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aristotle University Of Thessaloniki Academic / other |
| Locations | 1 site (Thessaloniki, Central Macedonia) |
| Trial ID | NCT05573997 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical significance of novel echocardiographic indices, particularly myocardial work parameters, in patients hospitalized for heart failure. It will track these indices from admission to discharge to better understand the various phenotypes of heart failure and their underlying pathophysiology. The study will also explore correlations between these echocardiographic indices and clinical, biochemical, and therapeutic data, assessing their prognostic implications. By identifying new heart failure sub-phenotypes, the research seeks to enhance treatment strategies for this diverse patient population.
Who should consider this trial
Good fit: Ideal candidates include adults acutely admitted with symptoms of heart failure and abnormal levels of specific biomarkers.
Not a fit: Patients with heart failure due to congenital heart disease, recent cardiac surgery, or those with poor echocardiographic windows may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification and management of heart failure sub-phenotypes, ultimately enhancing patient outcomes.
How similar studies have performed: While the approach of using novel echocardiographic indices is emerging, similar studies have shown promise in identifying heart failure phenotypes, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients acutely admitted at the Department of Cardiology of AHEPA University General Hospital, Thessaloniki, Greece with symptoms and/or signs of heart failure (HF), as those are defined by the European Society of Cardiology. 2. Patients with abnormal plasma concentration of N-terminal pro-B-type natriuretic peptide, measured within 24 hours from admission 3. Objective echocardiographic evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular (LV) systolic dysfunction/diastolic dysfunction/raised LV filling pressures upon admission assessment Exclusion Criteria: 1. Symptoms and/or signs of HF secondary to congenital heart disease, infective endocarditis, pericardial disease, and history of recent cardiac surgery (\<1 month) 2. Patients receiving maintenance hemodialysis 3. Patients with active malignancy and/or life expectancy \< 1 year 4. Poor echocardiographic acoustic windows precluding reliable assessment and/or analysis 5. Heart transplantation 6. Patients not providing informed written consent to participate in the study
Where this trial is running
Thessaloniki, Central Macedonia
- AHEPA University Hospital, Thessaloniki, Greece — Thessaloniki, Central Macedonia, Greece (Recruiting)
Study contacts
- Study coordinator: Stylianos Daios, MD, MSc
- Email: stylianoschrys.daios@gmail.com
- Phone: 6947529606
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.